PubRank
Search
About
R M Mackie
Author PubWeight™ 63.91
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Systemic complement activation in psoriasis vulgaris.
Clin Exp Dermatol
1996
1.94
2
Tanning with ultraviolet A sunbeds.
BMJ
1990
1.93
3
Postoperative depression of tumour-directed cell-mediated immunity in patients with malignant disease.
Br Med J
1972
1.84
4
Juvenile plantar dermatosis: a new entity?.
Clin Exp Dermatol
1976
1.51
5
Assessment of an anti-T-cell receptor variable region antibody panel in cutaneous T-cell lymphoma.
Br J Dermatol
1994
1.39
6
The suitability of SunCheck patches and Tanscan cards for monitoring the sunburning effectiveness of sunlight.
Br J Dermatol
1993
1.38
7
Health and the ozone layer.
BMJ
1988
1.37
8
UVA-induced melanocytic lesions.
Br J Dermatol
1987
1.35
9
Use of NK1 C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions.
J Clin Pathol
1984
1.14
10
Site-specific melanocytic naevus counts as predictors of whole body naevi.
Br J Dermatol
1988
1.09
11
Assessment of prognosis in patients with malignant melanoma.
Lancet
1972
1.05
12
Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi.
Br J Dermatol
1994
1.04
13
Assessment of a contact-plate sampling technique and subsequent quantitative bacterial studies in atopic dermatitis.
Br J Dermatol
1990
1.04
14
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
J Natl Cancer Inst
2010
1.04
15
Clinical accuracy of the diagnosis of cutaneous malignant melanoma.
Br J Dermatol
1998
1.03
16
Cell-mediated immunity in patients with malignant melanoma.
Br J Dermatol
1972
0.99
17
Loss of beta2 microglobulin from the cell surface of cutaneous malignant and premalignant lesions.
Br J Dermatol
1981
0.98
18
Sensitization to tumour-associated antigens in human breast carcinoma.
Int J Cancer
1974
0.97
19
Seven-point checklist for melanoma.
Clin Exp Dermatol
1991
0.96
20
The spectrum of mutations in erythrokeratodermias--novel and de novo mutations in GJB3.
Hum Genet
2000
0.93
21
Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study.
Br J Cancer
2001
0.93
22
An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina.
Br J Obstet Gynaecol
1998
0.92
23
Severe reaction to diphosphonate: implications for treatment of Paget's disease.
BMJ
1988
0.89
24
Leukocyte migration inhibition by cancer patients' sera.
Int J Cancer
1976
0.89
25
Serum anti-tumour antibodies and auto-antibodies in vitiligo.
Br J Dermatol
1975
0.88
26
The prescription of isotretinoin to women: is every precaution taken?
Br J Dermatol
1998
0.88
27
Tioconazole nail solution--an open study of its efficacy in onychomycosis.
Clin Exp Dermatol
1985
0.87
28
Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease.
Br J Dermatol
1996
0.87
29
Plantar malignant melanoma in a white Caucasian population.
Br J Dermatol
1993
0.87
30
Letter: Formalin-fixed tumour cells in the leukocyte migration test.
Lancet
1973
0.86
31
An audit of the completeness of non-melanoma skin cancer registration in Greater Glasgow.
Br J Dermatol
1997
0.86
32
Lupus erythematosus in association with finger-clubbing.
Br J Dermatol
1973
0.85
33
An assessment of the diagnostic value of the monoclonal antibodies Leu 8, OKT9, OKT10 and Ki67 in cutaneous lymphocytic infiltrates.
Br J Dermatol
1986
0.85
34
Pustular psoriasis in association with renal amyloidosis.
Br J Dermatol
1974
0.85
35
The effect of treatment with 13-cis-retinoic acid on the metabolic burst of peripheral blood neutrophils from patients with acne.
Br J Dermatol
1991
0.85
36
Natural-killer-cell activity in atopic dermatitis.
Clin Allergy
1984
0.83
37
The relationship between immunological parameters and response to therapy in resistant oral candidosis.
Br J Dermatol
1978
0.83
38
Formalinized tumour cells in the leucocyte migration inhibition test.
Clin Exp Immunol
1975
0.83
39
Staphylococcus aureus and intra-nasal mupirocin in patients receiving isotretinoin for acne.
Br J Dermatol
1992
0.82
40
Plasma zinc in psoriatic in-patients treated with local zinc applications.
Br J Dermatol
1980
0.81
41
The use of a double-label immunoperoxidase monoclonal antibody technique in the investigation of patients with mycosis fungoides.
Br J Dermatol
1982
0.80
42
A multicentre phase II trial of vindesine in malignant melanoma.
Eur J Cancer Clin Oncol
1982
0.80
43
Tumor-directed cellular immunity in malignant melanoma and its modification by surgical treatment.
Yale J Biol Med
1973
0.80
44
Indirect leukocyte migration assay in patients with malignant melanoma.
Int J Cancer
1979
0.80
45
An examination of the immunology of cancer patients.
Int J Cancer
1976
0.79
46
The contribution of direct immunofluorescence to the diagnosis of lupus erythematosus.
J Cutan Pathol
1989
0.79
47
Keratinocyte expression of intercellular adhesion molecule 1 (ICAM-1) correlated with infiltration of lymphocyte function associated antigen 1 (LFA-1) positive cells in evolving allergic contact dermatitis reactions.
Histopathology
1991
0.79
48
Human melanoma cell-derived factor(s) stimulate fibroblast glycosaminoglycan synthesis.
Int J Cancer
1992
0.79
49
The effect of topical steroid application on natural killer cell activity.
Clin Exp Allergy
1989
0.79
50
The role of sunlight in the aetiology of cutaneous malignant melanoma.
Clin Exp Dermatol
1981
0.79
51
Localization of transforming growth factor-alpha RNA and protein in the skin of psoriatic patients receiving therapy.
Br J Dermatol
1994
0.79
52
In vitro reaction of cancer patients and others to Bacillus Calmette-Gueérin.
Int J Cancer
1980
0.79
53
The unexpected sites of melanoma regional recurrences.
J Plast Reconstr Aesthet Surg
2006
0.79
54
Personal solar UV-A doses received by patients undergoing oral psoralen photochemotherapy for psoriasis.
Br J Dermatol
1981
0.79
55
The use of paraffin-processed tissue and the immunoperoxidase technique in the diagnosis of bullous diseases, lupus erythematosus and vasculitis.
Br J Dermatol
1982
0.78
56
A case of pagetoid reticulosis bearing the T cytotoxic suppressor surface marker on the lymphoid infiltrate: further evidence that pagetoid reticulosis is not a variant of mycosis fungoides.
Br J Dermatol
1984
0.78
57
Follicular mucinosis, mycosis fungoides, and acute myeloid leukemia.
J Clin Pathol
1990
0.78
58
The relationship between risk of death from clinical stage 1 cutaneous melanoma and thickness of primary tumour: no evidence for steps in risk. Scottish Melanoma Group.
Br J Cancer
1991
0.78
59
Novel variants of human papillomavirus type 2 in warts from immunocompromised individuals.
Br J Dermatol
1989
0.78
60
Cellular immunity in human malignant melanoma and melanoma histology.
Br J Cancer
1973
0.77
61
Pyoderma gangrenosum in infancy.
Acta Derm Venereol
1982
0.77
62
A quantitative analysis of the Langerhans cell in chronic plaque psoriasis.
Clin Exp Dermatol
1986
0.77
63
Intraoperative identification of sentinel lymph node in patients with malignant melanoma.
Br J Cancer
1997
0.77
64
Retinoic acid-induced inhibition of metastatic melanoma cell lung colonization and adhesion to endothelium and subendothelial extracellular matrix.
Clin Exp Metastasis
1992
0.77
65
Out-patient treatment of psoriasis: short contact and overnight dithranol therapy compared.
Br J Dermatol
1985
0.76
66
Cellular immunity to breast carcinoma and malignant melanoma.
Br J Cancer Suppl
1973
0.75
67
The melanoma epidemic. Excess exposure to ultraviolet light is established as major risk factor.
BMJ
1996
0.75
68
Comparative study of three methods of plastic embedding in diagnostic dermatopathology.
J Clin Pathol
1985
0.75
69
Management of cutaneous T cell lymphoma.
BMJ
1994
0.75
70
Not wanted at thirty-five.
Lancet
1979
0.75
71
Porphyria cutanea tarda and hyperkeratosis.
Br J Clin Pract
1972
0.75
72
Proceedings: Some aspects of the use of B.C.G. in the treatment of advanced malignant disease.
Br J Cancer
1974
0.75
73
Proceedings: cellular immunity to malignant melanoma.
Br J Surg
1973
0.75
74
Onycholysis occurring during PUVA therapy.
Clin Exp Dermatol
1979
0.75
75
The suitability of sunglasses used by patients following ingestion of psoralen.
Br J Dermatol
1988
0.75
76
Localized secondary telangiectasia in patients with thyroid disease.
Br J Dermatol
1973
0.75
77
Cutaneous lymphadenoma: a case report and review of the literature.
Br J Dermatol
1993
0.75
78
Distribution of T cell subsets and Langerhans cells in mycosis fungoides, and the effect of PUVA therapy.
Clin Exp Dermatol
1986
0.75
79
Wiskott-Aldrich syndrome with partial response to transfer factor.
Br J Dermatol
1978
0.75
80
Generalized eruptive histiocytoma.
Br J Dermatol
1992
0.75
81
Perspectives in dermatology: Great Britain (1972-1974).
Int J Dermatol
1975
0.75
82
Ultraviolet B radiation was increased at ground level in scotland during a period of ozone depletion.
Br J Dermatol
1997
0.75
83
The labial melanotic macule: a review of 79 cases.
Br J Dermatol
1997
0.75
84
Further evidence of the safety of tar in the management of psoriasis.
Br J Dermatol
1985
0.75
85
The mechanism of tumour cell induced inhibition of human leucocyte migration.
Eur J Cancer
1979
0.75
86
Topical econazole in cutaneous fungal infections.
Practitioner
1980
0.75
87
Ground-level solar spectral irradiance in Glasgow: an inter-comparison of two sites.
Photodermatol Photoimmunol Photomed
2004
0.75
88
Malignant melanoma and the Scottish Melanoma Group.
Health Bull (Edinb)
1986
0.75
89
Malignant melanomata: an aid to preoperative diagnosis.
Br J Surg
1972
0.75
90
The management of cutaneous malignant melanoma.
Clin Exp Dermatol
1982
0.75
91
Histological changes observed in the skin of patients with mycosis fungoides receiving photochemotherapy.
Clin Exp Dermatol
1980
0.75
92
Cutaneous and ocular side-effects of oral photochemotherapy: results of an 8-year follow-up study.
Br J Dermatol
1987
0.75
93
The immune response in human malignant melanoma.
Clin Exp Dermatol
1976
0.75
94
Proceedings: Immunity in patients with breast cancer.
Br J Cancer
1975
0.75
95
Evaluation and staging in the Scottish Dermatological Society mycosis fungoides register.
Bull Cancer
1977
0.75
96
Re-examining crude coal tar treatment for psoriasis.
Br J Dermatol
1992
0.75
97
A case of focal dermal hypoplasia.
Clin Exp Dermatol
1982
0.75
98
Allergic and irritant contact dermatitis compared in the treatment of alopecia totalis and universalis. A comparison of the value of topical diphencyprone and tretinoin gel.
Br J Dermatol
1989
0.75
99
Etretinate and visual function: a 1-year follow-up study.
Br J Dermatol
1991
0.75
100
Studies in cutaneous immunofluorescence. I. The effect of storage time on direct immunofluorescence of skin biopsies from bullous disease and lupus erythematosus.
J Cutan Pathol
1980
0.75
101
Current trends in the management of recurrent malignant melanoma.
Clin Exp Dermatol
1977
0.75
102
Immunological changes in cancer patients receiving BCG.
Dev Biol Stand
1978
0.75
103
Single-centre prospective study of isolated limb perfusion with melphalan in the treatment of subungual malignant melanoma.
Br J Surg
1995
0.75
104
Juvenile plantar dermatosis--an 8-year follow-up of 102 patients.
Clin Exp Dermatol
1987
0.75